Evaluating Important Advances in the Treatment of Lower-Risk Myelodysplastic Syndromes and the Specialty Pharmacist’s Role

This activity was originally broadcast live at the 2022 Asembia Specialty Pharmacy Summit.

Program Description

Once a diagnosis of myelodysplastic syndromes (MDS) is confirmed, patients are classified as having lower- or higher-risk disease using cytogenetic classification and prognostic scoring values. Therapeutic decisions are different for each risk stratification, and this program will focus on established therapies for lower-risk disease. Pharmacists need to be familiar not only with recommended standard treatment approaches for lower-risk disease but also with treatment strategies for patients with inadequate response to initial therapy or who develop MDS-associated anemia. Pharmacists on the multidisciplinary team can play an essential role in adverse effect monitoring and management, and their prompt intervention can improve outcomes in patients with MDS at risk of anemia or iron overload. Expert faculty will discuss efficacy and safety data for emerging and investigational agents for treatment of MDS or its secondary effects as well as essential elements of supportive care plans pharmacists can implement in practice.

Target audience: Specialty pharmacists and oncology pharmacists

Type of activity: Application
Release date: May 10, 2022
Expiration date: May 10, 2023

Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Classify risk stratification and scoring systems to differentiate therapeutic decisions for patients with lower-risk myelodysplastic syndromes (MDS) versus those with higher-risk disease
• Analyze recent and emerging data to select treatment regimens appropriate for patients with lower-risk MDS
• Identify therapies for secondary consequences of MDS, such as anemia, to improve quality of life and outcomes
• Explore a team-based approach for monitoring and managing patients with MDS at risk of anemia and iron overload

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-22-232-H01-P. The activity is available for CE credit through May 10, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Faculty

Robert Mancini, PharmD, BCOP, FHOPA, has the following relevant financial relationships with commercial interests to disclose:

Speakers Bureau: Takeda Pharmaceuticals, GlaxoSmithKline

Gregory D. Wolfe, PharmD, BCOP, CSP, LSSGB, has no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff— Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Amy Seung, PharmD, BCOP, FHOPA; Dipti Desai, PharmD, CHCP; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta have no financial relationships with commercial interests to disclose.

Anonymous peer reviewers have been used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

The content of this activity may include information regarding the use of products that may be inconsistent with, or outside the approved labeling for, these products in the United States. Pharmacists should note that the use of these products outside current approved labeling is considered experimental and are advised to consult the prescribing information for these products.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms